

Last Updated July 2020

Original Research

1. Ramos CA, Grover NS, Beaven AW, Lulla PD, Wu MF, Ivanova A, Wang T, Shea TC, Rooney CM, Dittus C, Park SI, Gee AP, Eldridge PW, McKay KL, Mehta B, Cheng CJ, Buchanan FB, Grilley BJ, Morrison K, Brenner MK, Serody JS, Dotti G, Heslop HE, **Savoldo B**. Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma. *J Clin Oncol*. 2020 Jul 23;JCO2001342. doi: 10.1200/JCO.20.01342. Epub ahead of print. PMID: 32701411.
2. Ma X, Shou P, Smith C, Chen Y, Du H, Sun C, Porterfield Kren N, Michaud D, Ahn S, Vincent B, **Savoldo B**, Pylayeva-Gupta Y, Zhang S, Dotti G, Xu Y. Interleukin-23 engineering improves CAR T cell function in solid tumors. *Nat Biotechnol*. 2020 Apr;38(4):448-459. doi: 10.1038/s41587-019-0398-2. Epub 2020 Feb 3. PMID: 32015548.
3. Fucà G, Reppel L, Landoni E, **Savoldo B**, Dotti G. Enhancing Chimeric Antigen Receptor T-Cell Efficacy in Solid Tumors. *Clin Cancer Res*. 2020 Jun 1;26(11):2444-2451. doi: 10.1158/1078-0432.CCR-19-1835. Epub 2020 Feb 3. PMID: 32015021; PMCID: PMC7269829.
4. Sun C, Shou P, Du H, Hirabayashi K, Chen Y, Herring LE, Ahn S, Xu Y, Suzuki K, Li G, Tzahouridis O, Su L, **Savoldo B**, Dotti G. THEMIS-SHP1 Recruitment by 4-1BB Tunes LCK-Mediated Priming of Chimeric Antigen Receptor-Redirected T Cells. *Cancer Cell*. 2020 Feb 10;37(2):216-225.e6. doi: 10.1016/j.ccell.2019.12.014. Epub 2020 Jan 30. PMID: 32004441.
5. Landoni E, Smith CC, Fucà G, Chen Y, Sun C, Vincent BG, Metelitsa LS, Dotti G, **Savoldo B**. A High-Avidity T-cell Receptor Redirects Natural Killer T-cell Specificity and Outcompetes the Endogenous Invariant T-cell Receptor. *Cancer Immunol Res*. 2020 Jan;8(1):57-69. doi: 10.1158/2326-6066.CIR-19-0134. Epub 2019 Nov 12. PMID: 31719055.
6. Laptewa N, Gilbert M, Diaconu I, Rollins LA, Al-Sabbagh M, Naik S, Krance RA, Tripic T, Hiregange M, Raghavan D, Dakhova O, Rouce RH, Liu H, Omer B, **Savoldo B**, Dotti G, Cruz CR, Sharpe K, Gates M, Orozco A, Durett A, Pacheco E, Gee AP, Ramos CA, Heslop HE, Brenner MK, Rooney CM. T-Cell Receptor Stimulation Enhances the Expansion and Function of CD19 Chimeric Antigen Receptor-Expressing T Cells. *Clin Cancer Res*. 2019 Dec 15;25(24):7340-7350. doi: 10.1158/1078-0432.CCR-18-3199. Epub 2019 Sep 26. PMID: 31558475.
7. Smith CC, Chai S, Washington AR, Lee SJ, Landoni E, Field K, Garness J, Bixby LM, Selitsky SR, Parker JS, **Savoldo B**, Serody JS, Vincent BG. Machine-Learning Prediction of Tumor Antigen Immunogenicity in the Selection of Therapeutic Epitopes. *Cancer Immunol Res*. 2019 Oct;7(10):1591-1604. doi: 10.1158/2326-6066.CIR-19-0155. Epub 2019 Sep 12. PMID: 31515258.
8. Xu X, Huang W, Heczey A, Liu D, Guo L, Wood M, Jin J, Courtney AN, Liu B, Di Pierro EJ, Hicks J, Barragan GA, Ngai H, Chen Y, **Savoldo B**, Dotti G, Metelitsa LS. NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced In

- Vivo Persistence and Antitumor Activity against Neuroblastoma. *Clin Cancer Res.* 2019 Dec 1;25(23):7126-7138. doi: 10.1158/1078-0432.CCR-19-0421. Epub 2019 Sep 4. PMID: 31484667.
9. Caratelli S, Arriga R, Sconocchia T, Ottaviani A, Lanzilli G, Pastore D, Cenciarelli C, Venditti A, Del Principe MI, Lauro D, Landoni E, Du H, **Savoldo B**, Ferrone S, Dotti G, Sconocchia G. In vitro elimination of epidermal growth factor receptor-overexpressing cancer cells by CD32A-chimeric receptor T cells in combination with cetuximab or panitumumab. *Int J Cancer.* 2020 Jan 1;146(1):236-247. doi: 10.1002/ijc.32663. Epub 2019 Oct 12. PMID: 31479522.
  10. Nehama D, Di Ianni N, Musio S, Du H, Patané M, Pollo B, Finocchiaro G, Park JJH, Dunn DE, Edwards DS, Damrauer JS, Hudson H, Floyd SR, Ferrone S, **Savoldo B**, Pellegatta S, Dotti G. B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres. *EBioMedicine.* 2019 Sep;47:33-43. doi: 10.1016/j.ebiom.2019.08.030. Epub 2019 Aug 26. PMID: 31466914.
  11. Sun C, Mahendravada A, Ballard B, Kale B, Ramos C, West J, Maguire T, McKay K, Lichtman E, Tuchman S, Dotti G, **Savoldo B**. Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma. *Oncotarget.* 2019 Mar 22;10(24):2369-2383.
  12. Du H, Hirabayashi K, Ahn S, Kren NP, Montgomery SA, Wang X, Tiruthani K, Mirlekar B, Michaud D, Greene K, Herrera SG, Xu Y, Sun C, Chen Y, Ma X, Ferrone CR, Pylayeva-Gupta Y, Yeh JJ, Liu R, **Savoldo B**, Ferrone S, Dotti G. Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells. *Cancer Cell.* 2019 Feb 11;35(2):221-237. PMID: 30753824.
  13. Ahn S, Li J, Sun C, Gao K, Hirabayashi K, Li H, **Savoldo B**, Liu R, Dotti G. Cancer Immunotherapy with T Cells Carrying Bispecific Receptors That Mimic Antibodies. *Cancer Immunol Res.* 2019 May;7(5):773-783. doi: 10.1158/2326-6066.CIR-18-0636. Epub 2019 Mar 6. PMID:30842091
  14. Chen Y, Sun C, Landoni E, Metelitsa L, Dotti G, **Savoldo B**. Eradication of Neuroblastoma by T Cells Redirected with an Optimized GD2-Specific Chimeric Antigen Receptor and Interleukin-15. *Clin Cancer Res.* 2019 May 1;25(9):2915-2924. doi: 10.1158/1078-0432.CCR-18-1811. Epub 2019 Jan 7. PMID: 30617136
  15. Grover NS, **Savoldo B**. Challenges of driving CD30-directed CAR-T cells to the clinic. *BMC Cancer.* 2019 Mar 6;19(1):203. doi: 10.1186/s12885-019-5415-9. PMID: 30841880.
  16. Ramos CA, Rouce R, Robertson CS, Reyna A, Narala N, Vyas G, Mehta B, Zhang H, Dakhova O, Carrum G, Kamble RT, Gee AP, Mei Z, Wu MF, Liu H, Grilley B, Rooney CM, Heslop HE, Brenner MK, **Savoldo B**, Dotti G. In Vivo Fate and Activity of Second-versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas. *Mol Ther.* 2018 Dec 5;26(12):2727-2737.
  17. Enblad G, Karlsson H, Gammelgård G, Wenthe J, Lövgren T, Amini RM, Wikstrom KI, Essand M, **Savoldo B**, Hallböök H, Höglund M, Dotti G, Brenner MK, Hagberg H, Loskog A. A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for

Lymphoma and Leukemia. Clin Cancer Res. 2018 Dec 15;24(24):6185-6194. doi: 10.1158/1078-0432.CCR-18-0426. Epub 2018 Aug 10. PMID:30097433

18. Hong LK, Chen Y, Smith CC, Montgomery SA, Vincent BG, Dotti G, **Savoldo B**. CD30-Redirected Chimeric Antigen Receptor T Cells Target CD30+ and CD30- Embryonal Carcinoma via Antigen-Dependent and Fas/FasL Interactions. Cancer Immunol Res. 2018 Oct;6(10):1274-1287. doi: 10.1158/2326-6066.CIR-18-0065. Epub 2018 Aug 7. PMID: 30087115
19. Pellegatta S, **Savoldo B**, Di Ianni N, Corbetta C, Chen Y, Patané M, Sun C, Pollo B, Ferrone S, DiMeco F, Finocchiaro G, Dotti G. Constitutive and TNF $\alpha$ -inducible expression of chondroitin sulfate proteoglycan 4 in glioblastoma and neurospheres: Implications for CAR-T cell therapy. Sci Transl Med. 2018 Feb 28;10(430). pii: eaao2731. doi: 10.1126/scitranslmed.aao2731. Erratum in: Sci Transl Med. 2018 Apr 4;10(435):.
20. Ramos CA, Ballard B, Zhang H, Dakhova O, Gee AP, Mei Z, Bilgi M, Wu MF, Liu H, Grilley B, Bollard CM, Chang BH, Rooney CM, Brenner MK, Heslop HE, Dotti G, **Savoldo B**. Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. J Clin Invest. 2017 Sep 1;127(9):3462-3471. doi: 10.1172/JCI94306. Epub 2017 Aug 14.
21. Liu E, Tong Y, Dotti G, Shaim H, **Savoldo B**, Mukherjee M, Orange J, Wan X, Lu X, Reynolds A, Gagea M, Banerjee P, Cai R, Bdaiwi MH, Basar R, Muftuoglu M, Li L, Marin D, Wierda W, Keating M, Champlin R, Shpall E, Rezvani K. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia. 2017 Jul 20. doi: 10.1038/leu.2017.226. [Epub ahead of print]
22. Heczey A, Louis CU, **Savoldo B**, Dakhova O, Durett A, Grilley B, Liu H, Wu MF, Mei Z, Gee A, Mehta B, Zhang H, Mahmood N, Tashiro H, Heslop HE, Dotti G, Rooney CM, Brenner MK. CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma. Mol Ther. 2017 Sep 6;25(9):2214-2224. Doi: 10.1016/j.ymthe.2017.05.012. Epub 2017 Jun 9.
23. Diaconu I, Ballard B, Zhang M, Chen Y, West J, Dotti G, **Savoldo B**. Inducible Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen Receptor-Modified T Cells. Mol Ther. 2017 Mar 1;25(3):580-592. doi: 10.1016/j.ymthe.2017.01.011. Epub 2017 Feb 8.
24. Ramos CA, **Savoldo B**, Torrano V, Ballard B, Zhang H, Dakhova O, Liu E, Carrum G, Kamble RT, Gee AP, Mei Z, Wu MF, Liu H, Grilley B, Rooney CM, Brenner MK, Heslop HE, Dotti G. Clinical responses with T lymphocytes targeting malignancy-associated  $\kappa$  light chains. J Clin Invest. 2016 Jul 1;126(7):2588-96. doi: PMID: 27270177
25. Xu Y, Chaudhury A, Zhang M, **Savoldo B**, Metelitsa LS, Rodgers J, Yustein JT, Neilson JR, Dotti G. Glycolysis determines dichotomous regulation of T cell subsets in hypoxia. J Clin Invest. 2016 Jul 1;126(7):2678-88. PMID: 27294526
26. Karlsson H, Svensson E, Gigg C, Jarvius M, Olsson-Strömberg U, **Savoldo B**, Dotti G, Loskog A. Evaluation of Intracellular signaling downstream Chimeric Antigen Receptors. PLoS One. 2015 23;10(12):e0144787. PMID: 26700307

27. Zhou X, Dotti G, Krance RA, Martinez CA, Naik S, Kamble RT, Durett AG, Dakhova O, **Savoldo B**, Di Stasi A, Spencer DM, Lin YF, Liu H, Grilley BJ, Gee AP, Rooney CM, Heslop HE, Brenner MK. Inducible caspase-9 suicide gene controls adverse effects from allopleteletate T cells after haploidentical stem cell transplantation. *Blood*. 2015 Jun 25;125(26):4103-13. PMID: 25977584
28. Ninomiya S, Narala N, Huye L, Yagyu S, **Savoldo B**, Dotti G, Heslop HE, Brenner MK, Rooney CM, Ramos CA Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. *Blood*. 2015 Jun 18;125(25):3905-16. PMID: 25940712.
29. Caruana I, **Savoldo B**, Hoyos V, Weber G, Liu H, Kim ES, Ittmann MM, Marchetti D, Dotti G. Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. *Nat Med*. 2015 May;21(5):524-9. PMID: 25849134.
30. Caruana I, Weber G, Ballard BC, Wood MS, **Savoldo B**, Dotti G. K562-Derived Whole-Cell Vaccine Enhances Antitumor Responses of CAR-Redirected Virus-Specific Cytotoxic T Lymphocytes In Vivo. *Clin Cancer Res*. 2015 Jul 1;21(13):2952-62. PMID: 25691731.
31. Arber C, Feng X, Abhyankar H, Romero E, Wu MF, Heslop HE, Barth P, Dotti G, **Savoldo B**. Survivin-specific T cell receptor targets tumor but not T cells. *J Clin Invest*. 2015 Jan;125(1):157-68. PMID: 25415440.
32. Nishio N, Diaconu I, Liu H, Cerullo V, Caruana I, Hoyos V, Bouchier-Hayes L, **Savoldo B**, Dotti G. Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors. *Cancer Res*. 2014 Sep 15;74(18):5195-205. PMID: 25060519.
33. Zhou X, Di Stasi A, Tey SK, Krance RA, Martinez C, Leung KS, Durett AG, Wu MF, Liu H, Leen AM, **Savoldo B**, Lin YF, Grilley BJ, Gee AP, Spencer DM, Rooney CM, Heslop HE, Brenner MK, Dotti G. Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene. *Blood*. 2014 Jun 19;123(25):3895-905. PMID: 24753538
34. Xu Y, Zhang M, Ramos CA, Durett A, Liu E, Dakhova O, Liu H, Creighton CJ, Gee AP, Heslop HE, Rooney CM, **Savoldo B**, Dotti G. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. *Blood*. 2014 Jun 12;123(24):3750-9. PMID: 24782509
35. Wen J, Li H, Tao W, **Savoldo B**, Foglesong JA, King LC, Zu Y, Chang CC. High throughput quantitative reverse transcription PCR assays revealing over-expression of cancer testis antigen genes in multiple myeloma stem cell-like side population cells. *Br J Haematol*. 2014;166(5):711-9. PMID: 24889268
36. Kennedy-Nasser AA, Ku S, Castillo-Caro P, Hazrat Y, Wu MF, Liu H, Melenhorst J, Barrett AJ, Ito S, Foster A, **Savoldo B**, Yvon E, Carrum G, Ramos CA, Krance RA, Leung K, Heslop HE, Brenner MK, Bollard CM. Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion

- of regulatory T cells without diminishing antiviral and antileukemic activity. *Clin Cancer Res.* 2014 Apr 15;20(8):2215-25.
37. Geldres C, **Savoldo B**, Hoyos V, Caruana I, Zhang M, Yvon E, Del Vecchio M, Creighton CJ, Ittmann M, Ferrone S, Dotti G. T Lymphocytes Redirected against the Chondroitin Sulfate Proteoglycan-4 Control the Growth of Multiple Solid Tumors both In Vitro and In Vivo. *Clin Cancer Res.* 2014 Feb 15;20(4):962-71.
  38. Perna SK, Pagliara D, Mahendravada A, Liu H, Brenner MK, **Savoldo B**, Dotti G. Interleukin-7 Mediates Selective Expansion of Tumor-redirected Cytotoxic T Lymphocytes (CTLs) without Enhancement of Regulatory T-cell Inhibition. *Clin Cancer Res.* 2014 Jan 1;20(1):131-9.
  39. Parmar S, Liu X, Tung SS, Robinson SN, Rodriguez G, Cooper LJ, Yang H, Shah N, Yang H, Konopleva M, Molldrem JJ, Garcia-Manero G, Najjar A, Yvon E, McNiece I, Rezvani K, **Savoldo B**, Bollard CM, Shpall EJ. Third-party umbilical cord blood-derived regulatory T cells prevent xenogenic graft-versus-host disease. *Cytotherapy.* 2014 Jan;16(1):90-100.
  40. Robinson SN, Thomas MW, Simmons PJ, Lu J, Yang H, Parmar S, Liu X, Shah N, Martín-Antonio B, Bollard C, Dotti G, **Savoldo B**, Cooper LJ, Najjar A, Rezvani K, Kaur I, McNiece IK, Champlin RE, Miller LP, Zweidler-McKay PA, Shpall EJ. Fucosylation with fucosyltransferase VI or fucosyltransferase VII improves cord blood engraftment. *Cytotherapy.* 2014 Jan;16(1):84-9.
  41. Casucci M, Nicolis di Robilant B, Falcone L, Camisa B, Norelli M, Genovese P, Gentner B, Gullotta F, Ponzoni M, Bernardi M, Marcatti M, Saudemont A, Bordignon C, **Savoldo B**, Ciceri F, Naldini L, Dotti G, Bonini C, Bondanza A. CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma. *Blood.* 2013 Nov 14;122(20):3461-72.
  42. Cruz CR, Micklethwaite KP, **Savoldo B**, Ramos CA, Lam S, Ku S, Diouf O, Liu E, Barrett AJ, Ito S, Shpall EJ, Krance RA, Kamble RT, Carrum G, Hosing CM, Gee AP, Mei Z, Grilley BJ, Heslop HE, Rooney CM, Brenner MK, Bollard CM, Dotti G. Infusion of donor-derived CD19-redirected-virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase I study. *Blood.* 2013 Oct 24;122(17):2965-73.
  43. Arber C, Abhyankar H, Heslop HE, Brenner MK, Liu H, Dotti G, **Savoldo B**. The immunogenicity of virus-derived 2A sequences in immunocompetent individuals. *Gene Ther.* 2013 Sep;20(9):958-62.
  44. Weber G, Gerdemann U, Caruana I, **Savoldo B**, Hensel NF, Rabin KR, Shpall EJ, Melenhorst JJ, Leen AM, Barrett AJ, Bollard CM. Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplant. *Leukemia.* 2013 Jul;27(7):1538-47.
  45. Chakraborty R, Mahendravada A, Perna SK, Rooney CM, Heslop HE, Vera JF, **Savoldo B**, Dotti G. Robust and cost effective expansion of human regulatory T cells highly functional in a xenograft model of graft versus host disease. *Haematologica.* 2013 Apr;98(4):533-7.

46. Engels EA, **Savoldo B**, Pfeiffer RM, Costello R, Zingone A, Heslop HE, Landgren O. Plasma Markers of B-Cell Activation and Clonality in Pediatric Liver and Hematopoietic Stem Cell Transplant Recipients. *Transplantation*. 2013 Feb 15;95(3):519-526.
47. Perna SK, De Angelis B, Pagliara D, Hasan ST, Zhang L, Mahendravada A, Heslop HE, Brenner MK, Rooney CM, Dotti G, **Savoldo B**. Interleukin 15 provides relief to cytotoxic T lymphocytes from regulatory T cell-mediated inhibition: implications for adoptive T-cell based therapies of lymphoma. *Clin Cancer Res*. 2013 Jan 1;19(1):106-17.
48. Ramos CA, Narala N, Vyas GM, Leen AM, Gerdemann U, Sturgis EM, Anderson ML, **Savoldo B**, Heslop HE, Brenner MK, Rooney CM. Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes for adoptive immunotherapy of HPV-associated malignancies. *Immunother*. 2013 Jan;36(1):66-76.
49. Robinson SN, Simmons PJ, Thomas MW, Brouard N, Javni JA, Trilok S, Shim JS, Yang H, Steiner D, Decker WK, Xing D, Shultz LD, **Savoldo B**, Dotti G, Bollard CM, Miller L, Champlin RE, Shpall EJ, Zweidler-McKay PA. Ex vivo fucosylation improves human cord blood engraftment in NOD-SCID IL-2R $\gamma$ (null) mice. *Exp Hematol*. 2012 Jun;40(6):445-56.
50. Chakraborty R, Rooney C, Dotti G, **Savoldo B**. Changes in chemokine receptor expression of regulatory T cells after ex vivo culture. *J Immunother*. 2012 May;35(4):329-36.
51. White RE, Ramer PC, Naresh KN, Meixlsperger S, Pinaud L, Rooney C, **Savoldo B**, Coutinho R, Bodor C, Gribben J, Ibrahim HA, Bower M, Nourse JP, Gandhi MK, Middeldorp J, Cader FZ, Murray P, Munz C, Allday MJ. EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors. *J Clin Invest*. 2012 Apr 2;122(4):1487-502.
52. Altvater B, Pscherer S, Landmeier S, Kailayangiri S, **Savoldo B**, Juergens H, Rossig C. Activated human  $\gamma\delta$  T cells induce peptide-specific CD8 $^+$  T-cell responses to tumor-associated self-antigens. *Cancer Immunol Immunother*. 2012;61(3):385-96.
53. Gerdemann U, Katari U, Christin AS, Cruz CR, Tripic T, Rousseau A, Gottschalk SM, **Savoldo B**, Vera JF, Heslop HE, Brenner MK, Bollard CM, Rooney CM, Leen AM. Cytotoxic T Lymphocytes Simultaneously Targeting Multiple Tumor-associated Antigens to Treat EBV Negative Lymphoma. *Mol Ther*. 2011; 12:2258-68.
54. Huye LE, Nakazawa Y, Patel MP, Yvon E, Sun J, **Savoldo B**, Wilson MH, Dotti G, Rooney CM Combining mTor Inhibitors With Rapamycin-resistant T Cells: A Two-pronged Approach to Tumor Elimination. *Mol Ther*. 2011; 12:2239-48
55. Muralidharan S, Hanley PJ, Liu E, Chakraborty R, Bollard C, Shpall E, Rooney C, **Savoldo B**, Rodgers J, Dotti G. Activation of wnt signaling arrests effector differentiation in human peripheral and cord blood-derived T lymphocytes. *J Immunol*. 2011;187:5221-32.
56. Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, Straathof K, Liu E, Durett AG, Grilley B, Liu H, Cruz CR, **Savoldo B**, Gee AP, Schindler J, Krance RA,

- Heslop HE, Spencer DM, Rooney CM and Brenner MK. Clinically Effective Safety Switch for Cellular Therapy using an Inducible Component of the Apoptotic Pathway. *N Engl J Med.* 2011;365(18):1673-83
57. Louis CU, **Savoldo B**, Dotti G, Pule M, Yvon E, Myers GD, Rossig C, Russell HV, Diouf O, Liu E, Liu H, Wu MF, Gee AP, Mei Z, Rooney CM, Heslop HE, Brenner MK Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. *Blood.* 2011;118(23):6050-6.
  58. Shaffer DR, **Savoldo B**, Yi Z, Chow KK, Kakarla S, Spencer D, Dotti G, Wu MF, Liu H, Kenney S, Gottschalk S. T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies. *Blood.* 2011; 117(16):4304-14.
  59. Quintarelli C, Dotti G, Hasan ST, De Angelis B, Hoyos V, Errichiello S, Mims M, Luciano L, Shafer J, Leen AM, Heslop HE, Rooney CM, Pane F, Brenner MK, **Savoldo B**. High-avidity cytotoxic-T-lymphocytes specific for a new preferentially expressed antigen of melanoma (PRAME)-derived peptide can target leukemic- and leukemic-precursor cells. *Blood.* 2011;117(12):3353-62.
  60. Kohn DB, Dotti G, Brentjens R, **Savoldo B**, Jensen M, Cooper LJ, June CH, Rosenberg S, Sadelain M, Heslop HE. CARs in the clinic. *Mol Ther.* 2011;19(3):432-8.
  61. **Savoldo B**, Ramos CA, Liu E, Mims M, Keating M, Carrum G, Kamble R, Bollard CM, Gee GP, Mei Z, Liu H, Grilley B, Rooney CM, Heslop HE, Benner MK, Dotti G. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. *J Clin Inv* 2011; 121(5):1822-6.
  62. Giordano Attianese GM, Marin V, Hoyos V, **Savoldo B**, Pizzitola I, Tettamanti S, Agostoni V, Parma M, Ponzoni M, Bertilaccio MT, Ghia P, Biondi A, Dotti G, Biagi E. In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor. *Blood.* 2011;117(18):4736-45
  63. Micklethwaite KP, **Savoldo B**, Hanley PJ, Leen AM, Demmler-Harrison GJ, Cooper LJ, Liu H, Gee AP, Shpall EJ, Rooney CM, Heslop HE, Brenner MK, Bollard CM, Dotti G. Derivation of human T-lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation. *Blood.* 2010;115(13):2695-703.
  64. Hoyos V, **Savoldo B**, Quintarelli C, Mahendravada A, Zhang M, Vera J, Heslop HE, Rooney CM, Brenner MK, Dotti G. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. *Leukemia.* 2010; 6:1160-70.
  65. Cruz CR, Hanley PJ, Liu H, Torrano V, Lin YF, Arce JA, Gottschalk S, **Savoldo B**, Dotti G, Louis CU, Leen AM, Gee AP, Rooney CM, Brenner MK, Bollard CM, Heslop HE. Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience. *Cytotherapy.* 2010; 6:743-9.
  66. Sun J, Dotti G, Huye LE, Foster AE, **Savoldo B**, Gramatges MM, Spencer DM, Rooney CM. T Cells Expressing Constitutively Active Akt Resist Multiple Tumor-associated Inhibitory Mechanisms. *Mol Ther.* 2010; 11:2006-17.

67. Foster AE, Okur FV, Biagi E, Lu A, Dotti G, Yvon E, **Savoldo B**, Carrum G, Goodell MA, Heslop HE, Brenner MK. Selective elimination of a chemoresistant side population of B-CLL cells by cytotoxic T lymphocytes in subjects receiving an autologous hCD40L/IL-2 tumor vaccine. *Leukemia*. 2010 Mar; 24(3):563-72.
68. Yvon E, Del Vecchio M, **Savoldo B**, Hoyos V, Dutour A, Anichini A, Dotti G, Brenner MK. Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells. *Clin Cancer Res*. 2009 Sep 15;15(18):5852-60.
69. De Angelis B, Dotti G, Quintarelli C, Huye LE, Zhang L, Zhang M, Pane F, Heslop HE, Brenner MK, Rooney CM, **Savoldo B**. Generation of Epstein-Barr-virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506). *Blood*. 2009;114(23):4784-91.
70. Foster AE, Okur FV, Biagi E, Lu A, Dotti G, Yvon E, **Savoldo B**, Carrum G, Andreeff M, Goodell MA, Heslop HE, Brenner MK. Selective depletion of a minor subpopulation of B-chronic lymphocytic leukemia cells is followed by a delayed but progressive loss of bulk tumor cells and disease regression. *Mol Cancer*. 2009; 8:106.
71. Tsang V, Yacoub M, Sridharan S, Burch M, Radley-Smith R, Khaghani A, **Savoldo B**, Amrolia PJ. Late donor cardiectomy after paediatric heterotopic cardiac transplantation. *Lancet*. 2009;374(9687):387-92.
72. Dotti G\*, Tian M\*, **Savoldo B\***, Najjar A, Cooper LJ, Jackson J, Smith A, Mawlawi O, Uthamanthil R, Borne A, Brammer D, Paolillo V, Alauddin M, Gonzalez C, Steiner D, Decker WK, Marini F, Kornblau S, Bollard CM, Shpall EJ, Gelovani JG. Repetitive noninvasive monitoring of HSV1-tk-expressing T cells intravenously infused into nonhuman primates using positron emission tomography and computed tomography with 18F-FEAU. *Mol Imaging*. 2009; 8(4):230-7. \*co-first authors
73. Di Stasi A, De Angelis B, Rooney CM, Zhang L, Mahendravada A, Foster AE, Heslop HE, Brenner MK, Dotti G, **Savoldo B**. T lymphocytes co-expressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and anti-tumor activity in a Hodgkin's tumor model. *Blood* 2009; 113(25):6392-402.
74. Hanley PJ, Cruz CR, **Savoldo B**, Leen AM, Stanojevic M, Khalil M, Decker W, Molldrem JJ, Liu H, Gee AP, Rooney CM, Heslop HE, Dotti G, Brenner MK, Shpall EJ, Bollard CM. Functionally active virus-specific T-cells that target CMV, adenovirus and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. *Blood*. 2009; 114(9):1958-67.
75. Steiner D, Gelovani J, **Savoldo B**, Robinson SN, Decker WK, Brouard N, Najjar A, Xing D, Yang H, Li S, Marini F, Zweidler-McKay PA, Bollard CM, Shpall EJ, Dotti G, Simmons PJ. Noninvasive Bioluminescent Imaging Demonstrates Long-Term Multilineage Engraftment of Ex Vivo-Expanded CD34-Selected Umbilical Cord Blood Cells. *Stem Cells*. 2009, 27(8):1932-1940.
76. Sashihara J, Burbelo PD, **Savoldo B**, Pierson TC, Cohen JI. Human antibody titers to Epstein-Barr Virus (EBV) gp350 correlate with neutralization of infectivity better than

- antibody titers to EBV gp42 using a rapid flow cytometry-based EBV neutralization assay. *Virology*. 2009 Sep 1;391(2):249-56.
77. Sun W, Yu Y, Dotti G, Shen T, Tan X, **Savoldo B**, Pass AK, Chu M, Zhang D, Lu X, Fu S, Lin X, Yang J. PPM1A and PPM1B act as IKKbeta phosphatases to terminate TNFalpha-induced IKKbeta-NF-kappaB activation. *Cell Signal* 2009 Jan;21(1):95-102.
  78. Pule MA, **Savoldo B**, Myers GD, Rossig C, Russell HV, Dotti G, Huls MH, Liu E, Gee AP, Mei Z, Yvon E, Weiss HL, Liu H, Rooney CM, Heslop HE, Brenner MK. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. *Nat Med*. 2008;14:1264-70.
  79. Ahmed N, Ratnayake M, **Savoldo B**, Perlaky L, Dotti G, Wels WS, Bhattacharjee MB, Gilbertson RJ, Shine HD, Weiss HL, Rooney CM, Heslop HE, Gottschalk S. Regression of experimental medulloblastoma following transfer of HER2-specific T cells. *Cancer Res*. 2007; 67(12):5957-64.
  80. Kaka AS, Rooney CM, **Savoldo B**. What influence has B-cell depletion on viral infections? *Leuk Lymphoma*. 2007 Jul;48(7):1257-8.
  81. **Savoldo B**, Rooney CM, Di Stasi A, Abken H, Hombach A, Foster AE, Zhang L, Heslop HE, Brenner MK, Dotti G. Epstein barr virus-specific cytotoxic T lymphocytes expressing the anti-CD30{zeta} artificial chimeric T-cell receptor for immunotherapy of Hodgkin's disease. *Blood*. 2007;110: 2620.
  82. C. Quintarelli, J. Vera, **B. Savoldo**, G. Giordano, A. Foster, M. Pule, Helen M. Heslop, C. Rooney, Malcolm K. Brenner, G. Dotti. Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor specific cytotoxic T lymphocytes. *Blood*. 2007; 110: 2793.
  83. Lee TC, **Savoldo B**, Barshes NR, Rooney CM, Heslop HE, Gee AP, Caldwell Y, Scott J, Goss JA. Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients. *Clinical Transplant*. 2006; 3:389.
  84. **Savoldo B**, Goss G, Hammer M, Zhang Z, Lopez T, Gee AP, Lin YF, Quiros-Tejeira R, Reinke P, Schubert S, Gottschalk S, Finegold M, Brenner MK, Rooney CM, Heslop HE, Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTL). *Blood*. 2006;108:2942.
  85. Lee T, Goss J, Rooney CM, Heslop HE, Barshes N, Caldwell Y, Gee AP, Scott J, **Savoldo B**. Quantification of a low cellular immune response to aid in identification of pediatric liver transplant recipients at high risk for EBV infection. *Clinical Transpl*. 2006; 20:689.
  86. Vera J, **Savoldo B**, Vigouroux S, Biagi E, Pule M, Rossig C, Wu J, Heslop HE, Rooney CM, Brenner MK and Dotti G. T-lymphocytes Redirected Against the Kappa Light Chain of Human Immunoglobulins Efficiently Kill Mature B-Lymphocyte Derived Malignant Cells. *Blood*. 2006; 108:3890.

87. **Savoldo B**, Rooney CM, Quiros-Tejeira RE, Caldwell Y, Wagner HJ, Lee T, Finegold MJ, Dotti G, Heslop HE, Goss JC. Immunity To Epstein-Barr Virus In Liver Transplant Recipients Treated With Rituximab For Post-Transplant Lymphoproliferative Disease. *Am J Transplantation*. 2005; 5: 566.
88. Dotti G, **Savoldo B**, Pule M, Straathof KC, Biagi E, Yvon E, Vigouroux S, Brenner MK, Rooney CM Human cytotoxic T-lymphocytes with reduced sensitivity to Fas-induced apoptosis. *Blood*. 2005; 105:4677.
89. Lee TC, **Savoldo B**, Rooney CM, Heslop HE, Gee AP, Caldwell Y, Barshes NR, Scott J, Bristow JL, O'Mahony CA, Goss JA. Quantitative EBV Viral Loads and Immunosuppression Alterations can Decrease PTLD Incidence in Pediatric Liver Transplant Recipients. *Am J Transplant*. 2005; 5:2222.
90. Leen AM, Sili U, **Savoldo B**, Jewell AM, Piedra PA, Brenner MK, Rooney CM. Fiber-modified adenoviruses generate sub-group cross-reactive, adenovirus-specific cytotoxic T lymphocytes for therapeutic applications. *Blood*. 2004; 103:1011.
91. Yotnda PN, **Savoldo B**, Charlet-Berguerand N, Rooney CM, Brenner MK. Targeted delivery of adenoviral vectors by cytotoxic T cells. *Blood*. 2004;104:2272.
92. **Savoldo B**, Cabbage M, Duret A, Goss J, Huls MH, Lopez T, Liu Z, Ling PD, Brenner MK, Heslop HE, Rooney CM. Generation of autologous Epstein-Barr virus (EBV)-specific CD(4+)cytotoxic T cells (CTL) from naive individuals. *J Immunol*. 2002;168:909-18.
93. Dotti G, **Savoldo B**, Yotnda P, Rill D, Brenner MK. Transgenic expression of CD40-ligand (CD40L) produces an in vivo antitumor immune response to both CD40 positive and negative Multiple Myeloma cells. *Blood*. 2002; 100:200.
94. **Savoldo B**, Huls MH, Liu Z, Okamura T, Volk HD, Reinke P, Sabat R, Babel N, Jones JM, Webster-Cyriaque J, Gee AP, Brenner MK, Heslop HE, Rooney CM. Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. *Blood*. 2002; 100:4059.
95. **Savoldo B**, Goss J, LZu , Huls MH, Doster S, Gee AP, Brenner MK, Heslop HE, Rooney CM. Generation of autologous Epstein Barr Virus (EBV)-specific cytotoxic T cells (CTL) for adoptive immunotherapy in solid organ transplant recipients. *Transplantation*. 2001; 72: 1078-86.
96. Dotti G, **Savoldo B**, Takahashi S, Goltsova T, Rill R, Rooney CM, Brenner MK. Adenovector Induced Expression Of Human-CD40L By Multiple Myeloma Cells: A Model For Immunotherapy. *Experimental Hematology*. 2001; 29: 952-61.
97. Bonati A, Carlo-Stella C, Lunghi P, Albertini R, Pinelli S, Migliaccio E, Sammarelli G, **Savoldo B**, Tabilio A, Dall'Aglio PP, Pelicci PG. Selective expression and constitutive phosphorylation of SHC proteins in the CD 34+ fraction of chronic myelogenous leukemia. *Cancer Research*. 2000; 60: 728-32.
98. Cilloni D, Garau D, Regazzi E, Sammarelli G, **Savoldo B**, Caramatti C, Mangoni L, Rizzoli V, Carlo-Stella C. Primitive hematopoietic progenitors within mobilized blood are spared by uncontrolled rate freezing. *Bone Marrow Transplant*. 1999; 23: 497-503.

99. Carlo-Stella C, Regazzi E, Sammarelli G, Colla S, Garau D, Gariz A, **Savoldo B**, Cilloni D, Tabilio A, Levitzki A, Rizzoli V. Effects of the tyrosine inhibitor AG957 and an Anti-Fas receptor antibody on CD34(+) chronic myelogenous leukemia progenitor cells. *Blood*. 1999; 93: 3373-82.
100. **Savoldo B**, Sammarelli G, Dotti G, Garau D, Regazzi E, Cilloni D, Tabilio A, Rizzoli V, Carlo-Stella C. Reverse transcription polymerase chain reaction is a reliable assay for detecting leukemic colonies generated by chronic myelogenous leukemia cells. *Leukemia*. 1998; 12: 434-40.
101. Carlo-Stella C, Regazzi E, Andrizzi C, **Savoldo B**, Garau D, Montefusco E, Vignetti M, Mandelli F, Rizzoli V, Meloni G. Use of granulocytes-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells. *Haematologica*. 1997; 82: 291-6.
102. Garau D, Regazzi E, **Savoldo B**, Sammarelli G, Rizzoli V, Carlo-Stella C. Detection of breast cancer cells using the magnetic cell separation (MACS) system: implication for stem cell purging. *Eur J Histochem*. 1997; 41(2): 17-8.
103. Carlo-Stella C, Dotti G, Mangoni L, Regazzi E, Garau D, Bonati A, Almici C, Sammarelli G, **Savoldo B**, Rizzo MT, Rizzoli V. Selection of Myeloid progenitors lacking BCR/ABL mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genestein. *Blood*. 1996; 88: 3091-100.